Neumora Therapeutics, Inc. Common Stock (NMRA)
NMRA Stock Price Chart
Explore Neumora Therapeutics, Inc. Common Stock interactive price chart. Choose custom timeframes to analyze NMRA price movements and trends.
NMRA Company Profile
Discover essential business fundamentals and corporate details for Neumora Therapeutics, Inc. Common Stock (NMRA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
15 Sept 2023
Employees
110.00
Website
https://www.neumoratx.comCEO
Daljit Singh Aurora
Description
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
NMRA Financial Timeline
Browse a chronological timeline of Neumora Therapeutics, Inc. Common Stock corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 27 Apr 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is -$0.34.
Earnings released on 6 Aug 2025
EPS came in at -$0.33 surpassing the estimated -$0.38 by +13.16%.
Earnings released on 12 May 2025
EPS came in at -$0.42 falling short of the estimated -$0.40 by -5.00%.
Earnings released on 3 Mar 2025
EPS came in at -$0.37 surpassing the estimated -$0.46 by +19.57%.
Earnings released on 12 Nov 2024
EPS came in at -$0.45 falling short of the estimated -$0.38 by -18.42%.
Earnings released on 6 Aug 2024
EPS came in at -$0.37 matching the estimated -$0.37.
Earnings released on 7 May 2024
EPS came in at -$0.34 surpassing the estimated -$0.35 by +2.86%.
Earnings released on 7 Mar 2024
EPS came in at -$0.71 falling short of the estimated -$0.65 by -9.23%.
Earnings released on 1 Nov 2023
EPS came in at -$1.14 falling short of the estimated -$0.36 by -216.67%.
Earnings released on 30 Jun 2023
EPS came in at -$0.25 .
Earnings released on 31 Mar 2023
EPS came in at -$0.23 .
Earnings released on 31 Dec 2022
EPS came in at -$0.19 .
Earnings released on 30 Sept 2022
EPS came in at -$0.19 .
Earnings released on 30 Jun 2022
EPS came in at -$0.20 .
Earnings released on 31 Mar 2022
EPS came in at -$0.28 .
Earnings released on 31 Dec 2021
EPS came in at -$0.18 .
Earnings released on 30 Sept 2021
EPS came in at -$1.17 .
Earnings released on 30 Jun 2021
EPS came in at -$0.11 .
Earnings released on 31 Mar 2021
EPS came in at -$0.10 .
Earnings released on 31 Dec 2020
EPS came in at -$0.13 .
NMRA Stock Performance
Access detailed NMRA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.